New discoveries in ovarian cancer and neurology—News of Note by Arlene Weintraub Monday, April 1, 2019 The week’s biotech discoveries included an I-O triple therapy against ovarian cancer and a single protein target for three diseases.
Germany joins CARB-X, commits €40M to fighting bacteria by Nick Paul Taylor Thursday, March 14, 2019 German officials put up the money as part of their decision to join U.S. and U.K. authorities in the CARB-X partnership.
Kaia home-training app can help manage COPD symptoms, study says by Conor Hale Monday, December 10, 2018 A pilot clinical study demonstrated how Kaia Health’s artificial intelligence-based smartphone app could reduce a patient’s COPD symptoms.
Implandata embeds glaucoma eye-pressure sensor in clinical trial by Conor Hale Monday, December 3, 2018 Implandata Ophthalmic successfully implanted a new version of its intraocular pressure sensor in its first patient in a first-in-human clinical trial.
New discoveries in brain diseases, immuno-oncology—News of Note by Arlene Weintraub Monday, November 19, 2018 The week’s biotech developments included a brain-penetrating compound from scorpion venom and a pact to develop virus-based cancer drugs.
Affimed tumbles as it puts brakes on T cell engager by Phil Taylor Tuesday, October 9, 2018 Affimed has halted work on trials of its lead T cell engager AFM11 for blood cancers after a death and two life-threatening events.
Philips pens €140M in solutions deals with German hospitals by Conor Hale Monday, July 16, 2018 Royal Philips signed two long-term consultancy deals in Germany to supply equipment and reform workflows as it transitions to a solutions provider.
Boehringer commits €230M to build German biologics center by Nick Paul Taylor Monday, June 25, 2018 Boehringer Ingelheim has unveiled a €230 million ($268 million) investment in its biologics capacity.
A 2-pronged attack could improve colon cancer therapy by Amirah Al Idrus Wednesday, May 16, 2018 Researchers in Germany pinpointed why targeting Notch and MAPK signaling individually may actually exacerbate colon cancer.
Sanofi, Evotec in infectious disease R&D transfer and license deal by Ben Adams Thursday, March 8, 2018 Sanofi will license out a host of infectious disease assets to Evotec, with 100 staffers also moving into its R&D engine.
